pone.0256937.s004.tif (3.04 MB)
Examining synergy with chemotherapeutics approved for first and second line treatment of ovarian cancer.
figure
posted on 2021-09-10, 17:35 authored by Ravi K. Anchoori, Logan George, Ssu-Hsueh Tseng, Brandon Lam, Srinidhi Polkampally, Anjali D. Amiano, Palmer Foran, Hannah Tsingine, Harideep Samanapally, Fernanda Carrizo Velasquez, Samarjit Das, Deyin Xing, Ahmad Bin Salam, Balasubramanyam Karanam, Chien-Fu Hung, Richard B. S. Roden(A) OVCAR5 (B) PEA2 (C) PEO4 (D) SKOV3 cells treated with titrated concentrations of RA413S and cisplatin in a checker board assay as triplicates and incubated for 72 h and the cell viability was measured using MTT assay. Data were analyzed and plotted in the Synergy web finder application and Zip scores derived [40]. (E) BR5 mouse model ovarian cancer cells (BRCA2 deficient) treated with RA413S and cisplatin (F) PEA1 cells treated with RA413S and doxorubicin (G) PEA2 cells treated with RA413S and doxorubicin (H) SKOV3 cells treated with RA414 and cisplatin.
(TIF)
History
Usage metrics
Categories
Keywords
xlink "> bortezomibproteasome &# 8217monomeric ubiquitin followingcombination approach warrantssynergistic cytotoxic responseirpn13s may compromiseubiquitin receptor rpn13evident upon treatmentcancer cell linesnew candidate irpn13sstress responseovarian cancercell lysatescandidate adrm1ubiquitination playssingle methylshow promiserapid accumulationprototypic inhibitorpotent analogsperinuclear clusteringoxidative stressmitochondrial depolarizationimproved bindingimportant roleearly biomarkercalled ra190asymmetry increasealternative non
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC